E-cigarettes vs. tobacco: The scientific report (2026 Update)

1. Introduction and Problem Statement

The global tobacco epidemic remains one of the most serious public health challenges. Despite decades of public awareness campaigns and stringent regulatory measures, a significant population of adult smokers remains, exhibiting a strong nicotine dependence and for whom complete abstinence from tobacco products presents an enormous obstacle. In this context, electronic cigarettes (e-cigarettes) have established themselves as a disruptive technology, redefining the paradigm of tobacco harm reduction. The central question addressed in this report, based on the request for clinical and toxicological evaluation, is: To what extent are e-cigarettes suitable for gradually reducing and ultimately eliminating nicotine consumption, and how does their potential for harm compare directly to that of conventional tobacco cigarettes?

This report synthesizes the current scientific evidence base as of 2024/2025. It is primarily based on systematic reviews by the Cochrane Collaboration, toxicological analyses by the German Federal Institute for Risk Assessment (BfR), statements by the German Cancer Research Center (DKFZ), and international data from the Office for Health Improvement and Disparities (OHID) in the UK and the World Health Organization (WHO). The aim is to present a comprehensive, nuanced, and evidence-based analysis that goes beyond simplistic statements and illuminates the complex interactions between usage patterns, chemical exposure, and clinical outcomes.

1.1 The concept of damage minimization

The scientific basis of e-cigarettes rests on decoupling nicotine absorption from the combustion of plant material. It is a toxicological consensus that the primary health risks of smoking – carcinogenesis, chronic obstructive pulmonary disease (COPD), and cardiovascular damage – are predominantly caused by the combustion products of tobacco (tar, carbon monoxide, polycyclic aromatic hydrocarbons), not primarily by nicotine itself. Nicotine is indeed the addictive substance., However, it has a significantly lower potential for somatic damage. than the smoke cocktail. E-cigarettes heat a liquid to create an aerosol, thereby the The formation of combustion pollutants is theoretically eliminated. or is drastically reduced.

2. Effectiveness of e-cigarettes in smoking cessation

The clinical efficacy of e-cigarettes as a cessation tool has long been the subject of intense debate. However, recent data analyses now allow for a more precise assessment, particularly in comparison to established nicotine replacement therapies (NRTs).

2.1 Evidence from Cochrane Systematic Reviews (2024/2025)

The Cochrane Collaboration, recognized worldwide for the highest standard in evidence-based medicine, has in its updated Living Systematic Review The available data was comprehensively assessed from January 2024 (with data collection up to February 2024). The analysis includes 90 completed studies, including 49 randomized controlled trials (RCTs), with a total population of over 29,000 participants.

The central finding of the review is of high clinical relevance: there is now high-certainty evidence that E-cigarettes containing nicotine are more effective as traditional nicotine replacement therapies (such as patches, gums, sprays) to achieve smoking abstinence of at least six months.

The statistical analysis shows a relative risk (RR) of 1.59 (95% confidence interval [CI] 1.30 to 1.93) in favor of the e-cigarette.

*Note: The comparison of e-cigarettes with nicotine vs. without nicotine also shows an advantage for the nicotine-containing variant (RR 1.46), which underlines the pharmacological necessity of nicotine for suppressing withdrawal symptoms.

In absolute numbers, this means that for every 100 smokers attempting to quit, approximately [number missing] will be eliminated through the use of e-cigarettes. four additional people successfully remain abstinent compared to NET. This superiority is often attributed to the combination of pharmacological effect (effective nicotine delivery) and the behavioral component (maintenance of the hand-to-mouth ritual, sensory “throat hit”), which is lacking in patches or chewing gum.

Another Cochrane Review from September 2023 The study compared e-cigarettes with the most effective prescription smoking cessation medications: varenicline and cytisine. The results suggest that e-cigarettes, varenicline, and cytisine have comparable effectiveness, with success rates ranging from 10–19% for e-cigarettes, 12–16% for varenicline, and 10–18% for cytisine. There were no statistically significant differences in effectiveness between these three interventions.

Many smokers use the Dual-use as a transition phase to switch completely to vaping in the long term.

This is a crucial finding for clinical practice: The e-cigarette is no longer just a consumer product, but in terms of its effectiveness is on par with pharmacological interventions, but with the advantage of widespread availability without a prescription (in most jurisdictions) and high acceptance among smokers.

2.2 The process of gradual reduction

The inquiry explicitly addresses “gradual reduction.” The Cochrane data confirm that e-cigarettes can also help smokers who don't want to quit abruptly but rather reduce their intake first. The availability of different nicotine strengths in e-liquids allows for “tapering,” where the user gradually reduces the nicotine dose.
However, experts warn that reducing cigarette consumption without the clear goal of quitting completely often leads to persistent dual use, which is problematic for health (see section 5). Data show that e-cigarettes are particularly effective when used as a complete substitute. However, the motivation to reduce consumption can be a valid starting point for quitting, as every day not smoked lowers exposure to combustion pollutants, unless this is offset by compensatory smoking (deeper inhalation of the remaining cigarettes).

2.3 Discrepancies in national data: The German perspective

While international evidence (UK, Cochrane) is positive, surveys from Germany, such as those conducted by the German Cancer Research Center (DKFZ), paint a more cautious picture. In older surveys (DEBRA study), only very few successful ex-smokers The German Cancer Research Center (DKFZ) reports having used e-cigarettes (e.g., 1 in 478 in a specific cohort). The DKFZ emphasizes that the majority of smokers (83%) attempt to quit without assistance. This discrepancy can be explained methodologically: Retrospective population surveys often capture consumer use without professional guidance and with older, inefficient devices (first-generation cigalikes). Clinical trials (RCTs), such as those analyzed by Cochrane, often use more modern devices and offer accompanying counseling. Furthermore, unlike in the UK, medical recommendations for e-cigarettes are not universally established in Germany, which could negatively impact success rates in real-world settings.

3. Toxicological profile: Aerosol vs. tobacco smoke

To answer the question “Are they less harmful?” in a well-founded manner, a detailed chemical analysis of the emissions is required. The fundamental difference lies in the process: combustion (tobacco cigarette, > 600 °C to 900 °C) vs. vaporization (e-cigarette, approx. 100 °C to 250 °C).

3.1 Qualitative and quantitative analysis of emissions

Tobacco smoke is a highly complex aerosol consisting of over 7,000 chemical compounds, including hundreds of toxins and at least 70 confirmed IARC Group 1 carcinogens. E-cigarette aerosol is chemically significantly less complex and consists of approximately 89–99% of the carrier substances propylene glycol (PG), vegetable glycerin (VG), water, nicotine and flavorings.

Studies by the Federal Institute for Risk Assessment (BfR) and international analyses show that the levels of harmful and potentially harmful substances (HPHCs) in e-cigarette aerosol are massively reduced compared to tobacco smoke.

The following table synthesizes data from BfR publications and comparative studies:

*Note: In studies, 15 puffs on an e-cigarette are often considered equivalent to one tobacco cigarette. However, the values ​​for e-cigarettes vary considerably depending on the device type (power/wattage) and e-liquid composition.

3.2 Interpretation of the pollutant reduction

The data consistently demonstrate a reduction of major carcinogens and toxins by often more than 95%.

• Volatile Organic Compounds (VOCs): Substances such as benzene and 1,3-butadiene, which are largely responsible for the cancer risk (e.g. leukemia) in smokers, are often barely detectable in e-cigarette vapor or are found at levels comparable to those in ambient air.
• Aldehydes Formaldehyde, acetaldehyde, and acrolein are produced in e-cigarettes through the thermal degradation of PG and VG. Their concentration is highly dependent on the temperature of the heating coil. Under proper use ("wet conditions"), the levels are low. The situation becomes critical during a so-called "dry puff" (when the wicking material runs dry), where aldehyde levels can rise sharply. However, since this taste is extremely unpleasant for users ("burnt"), this condition is avoided in practice.
• Metals: Traces of metals (nickel, chromium, lead) can migrate from the heating elements into the aerosol. Studies found levels that were sometimes higher than those of the ambient air, but mostly significantly below the workplace exposure limits and significantly below the values ​​in tobacco smoke.

3.3 Biomarker studies in humans

The theoretical reduction in aerosol is also reflected in the actual exposure of the body. Studies analyzing urine and blood samples from e-cigarette users (who had stopped smoking) showed significantly lower levels of biomarkers for pollutant exposure (BoE).

• One FDA and CDC study The study found 19% to 81% lower concentrations of biomarkers for tobacco-specific nitrosamines (TSNAs), metals and VOCs in exclusive e-cigarette users compared to smokers.
• The BfR cites studies in which the biomarkers for acrylonitrile (CEMA) and 1,3-butadiene (MHBMA) decreased by 86–97% after the switch.

This systemic relief of the body is a strong indication of the potential for damage minimization.

4. Pathophysiology and Cardiovascular Risks

While the risk of cancer decreases significantly due to the elimination of combustion products, the cardiovascular risk profile is more complex. Cardiovascular diseases are influenced by both particulate matter and oxidative stress, as well as by nicotine itself.

4.1 The role of nicotine and oxidative mechanisms

Nicotine has a sympathomimetic effect: it increases heart rate and blood pressure, constricts peripheral blood vessels, and increases myocardial oxygen demand. These effects occur with both smoking and vaping. Additionally, there is evidence that ultrafine particles and thermal degradation products in the aerosol can trigger oxidative stress. Studies have shown a Activation of inflammatory markers (e.g., p38 MAPK) and a deterioration of endothelial function (ability of vessels to dilate) after vaping. Arterial stiffness may temporarily increase.

However, e-cigarettes lack a crucial cardiovascular killer: Carbon monoxide (CO). CO binds to hemoglobin and reduces the oxygen transport capacity of the blood massive, which leads to chronic hypoxia and plaque instability in smokers. The elimination of CO is a significant advantage of e-cigarettes.

4.2 The Paradox of “Dual Use” (Dual Consumption)

A critical finding of recent research concerns so-called “dual use” – the simultaneous smoking and vaping. Many smokers use e-cigarettes to reduce their cigarette consumption (e.g., from 20 to 10 cigarettes), but do not quit completely.
A much-discussed Study by Boston University (published in Circulation) examined inflammation and stress biomarkers in dual users. The result was sobering:

• Participants who exclusively Those who vaped showed similar inflammation levels to non-smokers.
• Participants who as well as smoked as well as vaped (“Dual User”), showed Inflammation markers and oxidative stress at the same high level as exclusive smokers.

The conclusion is drastic: “Every cigarette counts.” The cardiovascular toxicity of smoking does not follow a linear dose-response curve; even small amounts of tobacco smoke are enough to activate platelets and trigger inflammatory cascades. A mere Reduction in the number of cigarettes smoked through e-cigarettes therefore no measurable cardiovascular benefit, as long as smoking continues. This is a key message for counseling: E-cigarettes are only an effective tool for risk reduction if they... complete smoking cessation (Complete Switch) enables.

5. Pulmonary Health: Facts, Myths, and Specific Diseases

The lungs are the entry point for aerosols. Here, scientific data often clash with myths spread by the media and singular events such as the EVALI crisis.

5.1 EVALI (E-cigarette or Vaping Product Use-Associated Lung Injury)

In 2019, the USA experienced an outbreak of severe, sometimes fatal, lung diseases, collectively known as EVALI. This led to widespread uncertainty worldwide.

• Investigation of the causes: Extensive investigations by the CDC and FDA identified Vitamin E acetate as the primary trigger. This substance was used as a thickening agent in illegal THC-containing vape cartridges (Black market hashish oil) is used. Vitamin E acetate clogs the alveoli in the lungs and leads to chemical pneumonia.
• Demarcation: Vitamin E acetate is not included in commercial, nicotine-containing e-liquids and is banned in regulated markets (such as the EU/UK). It was found in lung samples from EVALI patients in 48 out of 51 cases. Vitamin E acetate detected, but no typical e-liquid components were identified as the cause.
• Conclusion: EVALI was primarily a drug and black market problem, not an inherent risk of regular e-cigarettes. Since the substance was identified and action was taken against illegal dealers, the number of cases has decreased dramatically.

5.2 The myth of “popcorn lung” (bronchiolitis obliterans)

A persistent myth claims that e-cigarettes cause “popcorn lung”, an irreversible narrowing of the bronchioles.

• Background: The disease occurred in workers at popcorn factories who were exposed to extreme amounts of the flavoring agent. Diacetyl (buttery taste).
• Data situation: Early e-liquids (especially sweet flavors) sometimes contained diacetyl. However, the amounts are negligible compared to cigarettes. Tobacco cigarettes contain an average of about 336 µg of diacetyl per cigarette – that's about 750 times more than the amount found in diacetyl-containing e-cigarettes (approx. 9 µg per cartridge).
• Clinical reality: Although smokers are exposed to extremely high doses of diacetyl, "popcorn lung" is not a typical smoking disease. It occurs worldwide. not a single confirmed case of popcorn lung, which was causally linked to vaping. Furthermore, diacetyl is now banned as an ingredient in e-liquids in the EU and UK.

5.3 COPD and Asthma

E-cigarettes are not inert. The aerosol (especially PG) can be hygroscopic and dry out or irritate the airways. Studies suggest that e-cigarette use is associated with a increased risk of asthma and chronic bronchitis It may be associated with other health problems. Changes in the oral microbiome and increased protease activity in the lungs have also been observed. However, switching to e-cigarettes is usually advantageous compared to continuing to smoke. Clinical studies have shown a reduction in exacerbations and an improvement in subjective symptoms in COPD patients who switched to e-cigarettes, as the severe irritation caused by combustion particles is eliminated.

6. Other health aspects and risks

6.1 Oncological risk (long term)

Since cancer often has latency periods of 20 years, direct long-term epidemiological data are lacking. Risk assessment is carried out via the “cancer potency” analysis of emissions.
Due to the massive reduction in carcinogens (see Table 2), health authorities such as Public Health England estimate the cancer risk of e-cigarettes to be less than 0.5% to 1% of the risk of tobacco cigarettes. A residual risk remains, but is considered minimal compared to cigarettes.

6.2 Device Security

Reports of exploding e-cigarettes almost exclusively relate to improper use (e.g., mechanical mods without a protection circuit, loose batteries in trouser pockets). Modern, regulated devices have safety mechanisms.. Another risk is the oral ingestion of liquid by children (risk of poisoning), which is why childproof closures are essential.

6.3 Oral Health

New studies indicate Risks to the oral cavity Nicotine and its carrier substances can cause dry mouth (xerostomia), which promotes tooth decay. Changes in the oral microbiome and gingivitis are also discussed. Compared to "smoker's periodontitis" and the risk of oral cancer from tobacco, however, the risk is likely lower, although not zero.

7. Regulatory discrepancies: UK vs. WHO vs. Germany

The evaluation of e-cigarettes is highly controversial, not only scientifically but also politically. Two competing philosophical approaches exist within public health policy.

7.1 The “Harm Reduction” Approach (Great Britain)

Great Britain (OHID, Royal College of Physicians) is pragmatically pursuing the goal of minimizing damage.

• Mantra: “Vaping is at least 95% less harmful than smoking.“
• Policy: E-cigarettes are actively promoted as a smoking cessation aid. Programs like "Swap to Stop" distribute free starter kits to smokers. Some hospitals even allow vape shops on their premises. The goal is a “Smoke-Free 2030”, E-cigarettes are seen as a key technology.

7.2 The “Precautionary Principle” approach (WHO, DKFZ)

The WHO and German authorities (DKFZ) emphasize the precautionary principle.

• Focus: Protection of non-smokers and young people from starting to smoke (“gateway effect”), fear of smoking becoming normalized, uncertainty about long-term consequences.
• Attitude: E-cigarettes are “not harmless”. If used at all, they should only be a last resort for quitting smoking. Regulation should be strict (advertising bans, flavor bans, taxes) to prevent To reduce attractiveness to young people.
• Criticism: This approach is criticized by harm reduction advocates because it makes it more difficult for smokers to access a less harmful alternative and implicitly protects the status quo (cigarette consumption).

8. Conclusion and answer to the research question

The analysis of the available evidence allows for a differentiated answer to the user's request:

“E-cigarettes can help adult smokers gradually reduce their nicotine consumption and eventually quit altogether.”
Confirmed. The scientific evidence for this is strong (Cochrane, High Certainty). E-cigarettes are more effective than conventional nicotine replacement products and as effective as medication. They allow for a gradual reduction of the nicotine dose. However, success depends significantly on intention: Simply reducing consumption (“dual use”) without the will to quit offers hardly any health benefits. A complete switch to nicotine replacement must be the goal.

“Are they less harmful than conventional cigarettes?”
Yes, very likely significantly less harmful. Toxicologically, the aerosol is significantly cleaner than tobacco smoke. The levels of carcinogens and cardiovascular toxins (especially CO) are drastically reduced (95–99%).

• Limitation: They are not risk-free (“less harmful, not harmless”). Risks exist for the cardiovascular system (due to nicotine) and the lungs (irritation, unknown long-term consequences).
• Comparison: In comparison to the deadly danger of smoking (50% of regular users die from it), the e-cigarette represents a massive reduction in risk.

Recommendation for practical application

For adult smokers who want to quit, switching to e-cigarettes is an evidence-based, recommended strategy, especially if other methods have failed. The switch should be complete (no dual use). However, non-smokers, pregnant women, and young people are strongly advised against using e-cigarettes, as they have their own addictive potential and pose unnecessary health risks.

Tabular summary: Benefit-risk profile